These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24443277)

  • 1. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.
    Struemper H; Sale M; Patel BR; Østergaard M; Österborg A; Wierda WG; Hagenbeek A; Coiffier B; Jewell RC
    J Clin Pharmacol; 2014 Jul; 54(7):818-27. PubMed ID: 24443277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Ogura M; Hatake K; Tobinai K; Uchida T; Suzuki T; Terui Y; Yokoyama M; Maruyama D; Mori M; Jewell RC; Katsura K; Hotta T
    Jpn J Clin Oncol; 2013 May; 43(5):466-75. PubMed ID: 23456745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
    Hagenbeek A; Gadeberg O; Johnson P; Pedersen LM; Walewski J; Hellmann A; Link BK; Robak T; Wojtukiewicz M; Pfreundschuh M; Kneba M; Engert A; Sonneveld P; Flensburg M; Petersen J; Losic N; Radford J
    Blood; 2008 Jun; 111(12):5486-95. PubMed ID: 18390837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study.
    Coiffier B; Losic N; Rønn BB; Lepretre S; Pedersen LM; Gadeberg O; Frederiksen H; van Oers MH; Wooldridge J; Kloczko J; Holowiecki J; Hellmann A; Walewski J; Robak T; Petersen J
    Br J Haematol; 2010 Jul; 150(1):58-71. PubMed ID: 20408846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
    Nightingale G
    Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
    Reagan JL; Castillo JJ
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ofatumumab.
    Zhang B
    MAbs; 2009; 1(4):326-31. PubMed ID: 20068404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
    Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
    J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.
    Coiffier B; Lepretre S; Pedersen LM; Gadeberg O; Fredriksen H; van Oers MH; Wooldridge J; Kloczko J; Holowiecki J; Hellmann A; Walewski J; Flensburg M; Petersen J; Robak T
    Blood; 2008 Feb; 111(3):1094-100. PubMed ID: 18003886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion.
    Tempescul A; Bagacean C; Riou C; Bendaoud B; Hillion S; Debant M; Buors C; Berthou C; Renaudineau Y
    Eur J Haematol; 2016 Mar; 96(3):229-35. PubMed ID: 25911969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.
    Patton WN; Lindeman R; Butler AC; Kipps TJ; Jewell RC; Laubscher KH; Zhou YY; Lewis E; Sedoti D; Witman P; Fang L; Chan G
    Leuk Lymphoma; 2015; 56(10):2819-25. PubMed ID: 25721750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
    Czuczman MS; Fayad L; Delwail V; Cartron G; Jacobsen E; Kuliczkowski K; Link BK; Pinter-Brown L; Radford J; Hellmann A; Gallop-Evans E; DiRienzo CG; Goldstein N; Gupta I; Jewell RC; Lin TS; Lisby S; Schultz M; Russell CA; Hagenbeek A;
    Blood; 2012 Apr; 119(16):3698-704. PubMed ID: 22389254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ofatumumab.
    Sanford M; McCormack PL
    Drugs; 2010 May; 70(8):1013-9. PubMed ID: 20481657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ofatumumab for the treatment of chronic lymphocytic leukemia.
    Grosicki S
    Expert Rev Hematol; 2015 Jun; 8(3):265-72. PubMed ID: 25882470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
    Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
    Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
    Reagan JL; Castillo JJ
    Future Oncol; 2014 May; 10(7):1147-55. PubMed ID: 24947256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
    Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJ; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Osterborg A;
    J Clin Oncol; 2010 Apr; 28(10):1749-55. PubMed ID: 20194866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.